Navigation Links
Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
Date:7/21/2008

NEW YORK, July 21 /PRNewswire/ -- Ari Kiev, M.D., president of SPRI Clinical Trials, will be a featured speaker at the upcoming conference Wall Street Unplugged: The Trout Group Investor Seminar -- Management's Guide to Wall Street. The conference will be held on Wednesday, July 30, at Midtown Loft & Terrace, 267 Fifth Avenue in New York. The event is targeted to CEOs and CFOs at private and small and mid-cap life science companies to gain better insight into Wall Street and maximize communication with the investment community.

Dr. Kiev, a peak performance strategist and author of six books on trading psychology, will speak on "Risk-Reward and Valuation of Clinical Stage Compounds: Challenge Your Perspective." His presentation will cover investors' perceptions of early stage companies, advising biotech CEOs on the most effective ways to position clinical trial data to help achieve an optimum valuation.

"Biotech CEOs should challenge their perspectives on the industry and try to see valuation from an investor's point of view rather than that of a scientist," Dr. Kiev said. "There tends to be too much emphasis on hyperbole as to the novelty of the mechanism and the size of the market. Focusing too much on why the stock is going up or down can turn off investors who are looking for greater involvement by the company in the path to success in clinical trials."

Dr. Kiev founded SPRI (http://www.spriclinicaltrials.com) in 1970 to provide top rate clinical trial services to the pharmaceutical and biotech industry. With nearly 40 years of experience managing studies in the New York area, SPRI expanded internationally in 2003. Today, the company conducts studies throughout Eastern and Western Europe.


'/>"/>
SOURCE SPRI Clinical Trials
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
2. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
4. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
8. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
9. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
Breaking Medicine Technology:
(Date:8/24/2017)... Raton (PRWEB) , ... August 24, 2017 , ... ... dietary supplements that help people improve all aspects of their health and wellness, ... States. , The step represents a component of Natural Subsistence’s aggressive marketing strategy ...
(Date:8/24/2017)... ... August 24, 2017 , ... Indosoft Inc. announces the ... of contact center application development experience. It represents a complete redesign of ... Indosoft designed Q-Suite NG for simple integration. A full set of APIs allows ...
(Date:8/23/2017)... ... 23, 2017 , ... Jachimowicz Law Group is excited to announce ... 115. The office is located between Schiele and Pershing avenues, with convenient parking for ... can still call the office at 408-246-5500. , Jachimowicz Law Group has ...
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup for Electronic ... IT to create efficiencies in healthcare information exchange and a trusted advisor to the ... which featured keynote addresses by Donald W. Rucker, MD, head of the Office ...
(Date:8/23/2017)... ... 2017 , ... Nightingale College continues the semiannual Give Back Day tradition for ... College dedicates to serving and volunteering for organizations that provide indispensable resources to the ... that need a little extra help. , The College’s Give Back Day initiative ...
Breaking Medicine News(10 mins):